2-N-acteylamino-3-chloro-1,4-naphthoquinone | 1429756-60-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-N-acteylamino-3-chloro-1,4-naphthoquinone
• 英文别名: N-acetyl-4-chloro-N-(3-chloro-1,4-dioxonaphthalen-2-yl)benzamide
• CAS: 1429756-60-4
• 化学式: C₁₉H₁₁Cl₂NO₄
• 分子量: 388.207
• InChiKey: LCJXLNGYQMGGHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  71.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氯苯甲酰氯 、 N-(3-氯-1,4-二氢-1,4-二氧代-2-萘基)乙酰胺 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 25.25h， 以41%的产率得到2-N-acteylamino-3-chloro-1,4-naphthoquinone
  参考文献：
  名称：

  Synthesis and Characterization of Novel Unsymmetrical and Symmetrical 3-Halo- or 3-Methoxy-substituted 2-Dibenzoylamino-1,4-naphthoquinone Derivatives

  摘要：

  对称和不对称的3-卤代或3-甲氧基取代的2-二苯甲酰氨基-1,4-纳弗喹啉类似物通过氢化钠促进的双酰化反应合成，平均产率为45%，反应底物为2-氨基-3-氯-1,4-纳弗喹啉、2-氨基-3-溴-1,4-纳弗喹啉和2-氨基-3-甲氧基-1,4-纳弗喹啉。

  DOI：

  10.3390/molecules18021973

文献信息

• ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER
  申请人：IC-Medtech Corp.

  公开号：EP3490543A1

  公开（公告）日：2019-06-05
• VITAMIN C AND VITAMIN K COMPOUND FOR TREATING PANCREATIC CANCER
  申请人：IC-MedTech Corp.

  公开号：US20170333392A1

  公开（公告）日：2017-11-23

  Provided herein is a method of treating, preventing, or alleviating one or more symptoms of pancreatic cancer in a subject, comprising administering to the subject therapeutically effective amounts of (i) vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and (ii) a vitamin K compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
• ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE
  申请人：IC-MedTech Corp.

  公开号：US20190343794A1

  公开（公告）日：2019-11-14

  Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
• ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE
  申请人：IC-MedTech Corp.

  公开号：US20210361666A1

  公开（公告）日：2021-11-25

  Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.
• INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENT
  申请人：IC-MedTech Corp.

  公开号：US20220409577A1

  公开（公告）日：2022-12-29

  Provided herein is a method of treating or alleviating one or more symptoms of a tumor in a subject, comprising intratumorally administering to the subject a therapeutically effective amount of ascorbic acid and a quinone compound